Skip to main content

Table 3 Comparison of Clinical and imaging characteristics with different Ki67 status in three cohorts

From: A novel radiomics based on multi-parametric magnetic resonance imaging for predicting Ki-67 expression in rectal cancer: a multicenter study

Characteristic

Training

P1

In-valid

P2

Ex-valid

P3

Ki67 (L)

Ki67 (H)

Ki67 (L)

Ki67 (H)

Ki67 (L)

Ki67 (H)

(n = 37)

(n = 102)

(n = 14)

(n = 46)

(n = 10)

(n = 50)

Age(y)

63.27 ± 12.25

64.02 ± 11.1

0.733

66.29 ± 12.41

63.46 ± 13.64

0.491

67.6 ± 11.71

68.62 ± 9.45

0.766

Sex

  

0.695

  

0.751

  

0.47

 F

13

41

 

4

17

 

2

19

 

 M

24

61

 

10

29

 

8

31

 

CEA

  

0.562

  

0.759

  

0.485

 Negative

14

46

 

7

19

 

5

32

 

 Positive

23

56

 

7

27

 

5

18

 

NC

  

0.096

  

0.777

  

0.709

 Yes

7

35

 

4

17

 

2

15

 

 No

30

67

 

10

29

 

8

35

 

Location

  

0.568

  

0.135

  

0.687

 Upper

5

21

 

5

8

 

3

13

 

 Middle

15

42

 

3

23

 

4

27

 

 Low

17

39

 

6

15

 

3

10

 

LD(mm)

44.0(33.35)

42.6(24.5)

0.746

42.2(42.5)

45.0(30.0)

0.975

43.5(39.5)

49.7(33.2)

0.974

ID(mm)

14.7(6.5)

16.3(5.15)

0.376

12.4(6.8)

19.0(7.5)

0.304

13.2(4.6)

16.0(6.35)

0.008

CIR(%)

68.5(42.5)

90.0(50.0)

0.021

75.0(50.0)

80.0(50.0)

0.809

84.1(33.0)

85.0(33.1)

0.861

ADC value

0.89 ± 0.20

0.78 ± 0.17

0.001

0.87 ± 0.94

0.77 ± 0.13

0.01

0.86 ± 0.09

0.78 ± 0.1

0.01

EP

  

0.702

  

0.759

  

1

 Mild/Moderate

20

50

 

6

17

 

5

23

 

 Obvious

17

52

 

8

29

 

5

27

 

mrT stage

  

0.001

  

0.036

  

0.003

 T1

10

6

 

2

2

 

4

2

 

 T2

13

23

 

5

10

 

4

18

 

 T3

8

49

 

7

16

 

2

22

 

 T4

6

24

 

0

18

 

0

8

 

mrN stage

  

0.038

  

0.015

  

0.362

 N0

27

62

 

11

16

 

8

28

 

 N1

2

25

 

2

17

 

1

13

 

 N2

8

15

 

1

13

 

1

9

 

rM stage

  

0.112

  

1

  

0.577

 Negative

37

93

 

13

40

 

10

44

 

 Positive

0

9

 

1

6

 

0

6

 

mrCRM

  

0.043

  

0.154

  

0.04

 Negative

30

64

 

13

33

 

9

27

 

 Positive

7

38

 

1

13

 

1

23

 
  1. Sex, CEA, Neoadjuvant chemotherapy, tumor location, EP, mrT stage, mrN stage, rM stage, mrCRM status between two group was compared by Chi-square test. After homogeneity test, T-test was used to compared with Age, and ADC values. Man-Whitney U test was used to compared with CIR, LD, ID
  2. In-valid Internal validation, Ex-valid External validation, EP Enhancement pattern